TAK

TAKEDA PHARMACEUTICAL CO LTD

Tremor tracks 20 of its cancer trials. This is a large company with many drugs, so one trial matters less to it, and company-wide signals count for half.

Company-wide warning signs

These add points to every one of this company's trials.

2 insiders sold shares within a monthSince Nov 4, 2026+4.9

Trials

TAKTakeda
5Calm
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Signing up patientsPhase 3225 patientsMain results: Sep 15, 2028
TAKTakeda
5Calm
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
Signing up patientsPhase 31,200 patientsMain results: Nov 1, 2028
TAKTakeda
5Calm
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
FinishedPhase 1/2324 patientsMain results: Sep 29, 2026
TAKTakeda
5Calm
A Study of TAK-505 in Adults With Solid Tumors
Signing up patientsPhase 1/2151 patientsMain results: Aug 18, 2030
TAKTakeda
5Calm
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
FinishedPhase 3354 patientsMain results: Sep 22, 2026
TAKTakeda
5Calm
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
FinishedPhase 1/2248 patientsMain results: Mar 30, 2026
TAKTakeda
5Calm
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Signing up patientsPhase 1/2273 patientsMain results: Dec 26, 2028
TAKTakeda
5Calm
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Signing up patientsPhase 3183 patientsMain results: Sep 11, 2028
TAKTakeda
5Calm
A Study of Rusfertide in Japanese Adults With Polycythemia Vera
Signing up patientsPhase 29 patientsMain results: Oct 28, 2027
TAKTakeda
5Calm
A Study of Rusfertide in Adults With Polycythemia Vera in China
Not started yetPhase 224 patientsMain results: Jul 1, 2028
TAKTakeda
5Calm
A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
Running, no new patientsPhase 1/228 patientsMain results: Apr 16, 2025
TAKTakeda
5Calm
A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
Running, no new patientsPhase 356 patientsMain results: May 30, 2025
TAKTakeda
5Calm
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Running, no new patientsPhase 252 patientsMain results: Apr 27, 2025
TAKTakeda
5Calm
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Running, no new patientsPhase 227 patientsMain results: Jun 16, 2024
TAKTakeda
5Calm
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
FinishedPhase 1/2161 patientsMain results: Oct 29, 2024
TAKTakeda
5Calm
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Running, no new patientsPhase 3245 patientsMain results: Aug 12, 2022
TAKTakeda
5Calm
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Running, no new patientsPhase 1/259 patientsMain results: May 5, 2020
TAKTakeda
5Calm
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
FinishedPhase 3248 patientsMain results: Feb 27, 2024
TAKMillennium Pharmaceuticals, Inc.
5Calm
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
FinishedPhase 337 patientsMain results: Dec 6, 2023
TAKTakeda
5Calm
Ixazomib Rollover Study
FinishedPhase 232 patientsMain results: Jul 3, 2024

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

22 sales (20 not pre-planned) · 0 purchases

Platford Giles RichardPresident, IBU · Nov 4, 2026Sold 55,617 sharesabout $1.2 million · not pre-planned
Bitetti Teresa MariePresident, OBU · Nov 2, 2026Sold 46,609 sharesabout $974 thousand · not pre-planned
Duprey Lauren RusckowskiChief Transformation Officer · Sep 14, 2026Sold 34,535 sharesabout $640 thousand · not pre-planned
Plump Andrew StewartPresident, R&D · Sep 2, 2026Sold 116,191 sharesabout $2.1 million · pre-planned
Plump Andrew StewartPresident, R&D · Aug 19, 2026Sold 19,651 sharesabout $363 thousand · pre-planned
Greenway Nicola Deidre PetalChief Human Resources Officer · Aug 18, 2026

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

None in the last 12 months.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.